The purpose of the study is to see whether this approach reduces the chance of the cancer coming back in the abdomen or nearby areas. After surgery, patients will be monitored with regular physical checks, blood tests, and imaging scans such as computed tomography performed with and without contrast every four months for up to three years. The follow‑up schedule also records any serious complications or deaths that occur shortly after the operation.

The purpose of the trial is to determine how well this combination can shrink or control the disease. Participants receive the injection of epcoritamab and the pill of lenalidomide over several treatment cycles, with regular visits to check health, monitor the cancer’s response, and watch for any side effects. After the treatment period, patients continue to be followed to see how long any benefit lasts and to ensure safety.

The purpose of the study is to see if GSK6042981 works better than sunitinib malate in slowing down the growth of the cancer or stopping it from getting worse. Patients taking part in this study will be randomly assigned to receive either GSK6042981 or sunitinib malate, and both groups will know which medicine they are receiving. During the study, doctors will monitor how well the treatment is working and how long patients can go without their disease getting worse. Patients will also be asked about their quality of life and any side effects they may experience.

Throughout the study, doctors will collect tissue samples from tumors for laboratory testing, which may come from previously stored tissue or from a new biopsy. The study will also measure the levels of GSK6042981 in the blood and track various aspects of patient health, including how long patients live, how quickly the tumor responds to treatment, and whether the cancer gets worse after starting a different treatment following the study medicine. Patients will complete questionnaires about their symptoms and overall well-being to help researchers understand how the treatments affect daily life.

The purpose of the study is to compare the effectiveness and safety of the experimental drug with the doctor‑chosen standard treatments. After enrollment, participants are randomly assigned to receive either the test medication or one of the standard options and then are followed with regular clinic visits to monitor their health, side effects, and any changes in tumor size. Doctors use a set of criteria called RECIST to decide whether the cancer is growing, staying the same, or shrinking, and they track how long patients live without the disease getting worse, which is known as progression‑free survival. Quality of life is also measured using a questionnaire called EORTC QLQ-C30, and participants report any symptoms they experience throughout the study.

The purpose of the study is to determine the highest dose that can be given safely and the dose that should be used in later studies. This early‑stage, Phase I trial will give participants the drug in several treatment cycles lasting a few weeks each, with regular check‑ups to watch for side effects and to see how the cancer responds.

The drug is delivered intravenous, meaning it goes directly into the bloodstream through a small tube placed in a vein. Participants will stay at the clinic for a short period after each infusion while staff monitor vital signs and any possible reactions. Follow‑up visits will include simple scans and blood tests to track tumor size and overall health, and any problems will be recorded and treated according to standard medical guidelines.

The purpose of the study is to compare how well the new drug works against standard immunotherapy or observation in preventing cancer from coming back. Participants will be randomly placed into one of the three groups, receive the assigned treatment (a daily tablet for the new drug or an intravenous infusion for the immunotherapies), and then be monitored with regular doctor visits and imaging scans to check for any signs of the disease returning or new health issues over several years.

The purpose of the study is to see how the fluorescent drug spreads inside the tumor and nearby lymph nodes after chemoradiation but before regular durvalumab treatment begins. Participants undergo a procedure called fluorescence molecular bronchoscopy, where a thin, flexible tube with a special camera is inserted through the airway to look directly at the lungs and lymph nodes. The camera detects the glow from the drug, and the brightness is expressed as a tumor‑to‑background ratio, a simple number that compares how bright the tumor appears to the surrounding tissue; a higher number indicates better drug presence in the tumor.

After the bronchoscopy, patients are monitored for any side effects and have routine follow‑up visits to track their health over time. No additional experimental treatments are given beyond the standard care and the single imaging procedure. The information collected will help researchers understand where the drug goes in the body, which may guide future use of immunotherapy for this type of lung cancer.

The purpose of the study is to learn how safe the new drug is and whether it can improve outcomes when used before surgery (called neoadjuvant therapy), after surgery (called adjuvant therapy), or as extra treatment after the main therapy (called consolidation therapy). In the first part, participants receive the new drug combined with the chemotherapy drugs before any surgery to see if the tumor shrinks enough to allow an operation and to monitor side effects. In the second part, the new drug is given by itself after surgery to check safety and tolerance, and in the third part it is given after the main treatment to see if it can be safely added. Participants receive the medication by infusion, have regular check‑ups, may undergo surgery if it becomes possible, and are followed over time to watch for any health problems.

The purpose of the study is to evaluate the safety and tolerability of S241656 when used alone and, optionally, when combined with posaconazole in the listed blood cancers. Participants will receive the study drug for several treatment cycles, with regular check‑ups that include physical examinations, laboratory tests, and monitoring for any side effects. In the optional part of the trial, participants will also take the antifungal medication for a short period to see how it influences the study drug. The trial follows a step‑wise design that starts with a low dose and may increase it if safety criteria are met, and participants may continue treatment as long as it remains safe and they choose to remain in the study.

The purpose of the trial is to determine whether the new medicine works as well as, or better than, the standard treatment in patients who have not received prior therapy for this condition. This phase 3 investigation uses a randomized, open-label design, meaning participants are assigned by chance to one of the two drugs and both the study team and participants know which drug is being taken. After enrollment, participants receive daily medication and attend regular clinic visits for safety checks and imaging scans that monitor the tumor. The study follows each person until the cancer shows signs of worsening, which is measured as progression-free survival, or until side effects require stopping the medication.

The purpose of the study is to determine whether giving a single dose of Tocilizumab before the cancer drug ramantamig can lower the chance of this immune reaction compared with a placebo. Participants are randomly assigned to receive either the active medication or the inactive solution, and neither the medical team nor the participants know which one is given. After the injection, participants receive the cancer treatment and are observed for about four weeks for any signs of the immune reaction or other side effects.

The trial follows a double‑blind design, meaning the assignment is concealed, and it lasts until the end of the monitoring period after the first dose of the cancer drug. Safety checks, blood tests, and regular visits are used to record any problems that arise during the study.

The purpose of the study is to determine whether the new drug can keep the cancer from growing for a longer time than the usual chemotherapy options. Participants are randomly placed into one of two groups, meaning the assignment is made by chance rather than choice, and receive either the oral tablets of the test drug or one of the IV chemotherapy choices selected by the doctor. Treatment cycles are given every few weeks, and patients undergo regular blood tests, imaging scans, and symptom checks to track how the disease behaves.

The study continues until the cancer shows signs of getting worse, known as progression, or until side effects become too severe to keep treatment safe. Side effects are any unwanted changes in health that may occur because of the medication, and they are closely monitored by the medical team. Throughout the trial, participants receive standard supportive care to help manage any symptoms related to the disease or its treatment.

The main goal of the study is to see if the injectable letrozole works better than the oral Femara when both are given with ribociclib. Participants will be randomly assigned to one of the two treatment groups and will take the study medicines for several months, with regular check‑ups to monitor how the cancer is responding and to watch for side effects. The study does not involve any surgical procedures; all medicines are taken by mouth or by a simple injection into the muscle.

After the first dose, participants will return for clinic visits every few weeks during the first few months, then roughly every two to three months for the rest of the study. At each visit doctors will ask about symptoms, perform basic physical exams, and may order imaging tests such as scans to see if the cancer has grown or shrunk. The study continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop.

The purpose of the study is to evaluate how well this approach works in preventing the leukemia from returning. Participants first receive the chemotherapy drugs to prepare their bodies, then undergo the stem‑cell transplant, and afterward take medicines to reduce the risk of the donor cells causing problems. Follow‑up visits are scheduled over several months to monitor recovery and any side effects.

Reduced intensity conditioning means a milder pre‑transplant chemotherapy regimen designed to be easier on older or weaker patients. Haploidentical stem cell transplantation uses a donor who shares only half of the genetic markers, often a family member, making a transplant possible when a fully matched donor is unavailable. Post‑transplant cyclophosphamide is given shortly after the transplant to help prevent graft‑versus‑host disease, a condition where the new immune cells attack the patient’s own tissues. The study tracks how long patients stay free of disease, how quickly blood counts recover, and the overall safety of the treatment.

The study looks at two treatment options. One group receives a combination of an intravenous medicine named AK104 and an oral pill called Lenvatinib. AK104 is a laboratory‑made protein that helps the body’s immune system recognize and attack cancer cells. Lenvatinib is a tablet that blocks signals that tumors use to grow and form new blood vessels. The other group receives only Lenvatinib tablets.

The purpose of the study is to compare how well the combination therapy works versus the single drug in shrinking tumors. Participants are assigned at random to one of the two groups and will take the assigned medication for several months, with regular doctor visits, blood tests, and imaging scans to watch the cancer’s response and check for side effects.

Participants will first receive the stem‑cell product and, after a short interval, the expanded T‑cell product, each as a single intravenous infusion. After each infusion, patients will remain in the hospital for observation and will have regular check‑ups, blood tests, and physical examinations to look for any side effects or problems. The study will continue to follow each participant for several months, recording any changes in the cancer and overall health, with the goal of learning how the treatments are tolerated and whether they show any early signs of benefit.

The main goal is to see whether adding PVEK to the standard pair of Venetoclax and Azacitidine can increase the rate of complete remission and help patients live longer, measured as overall survival. Participants will receive the medicines in regular cycles over several months, with clinic visits for dosing, blood tests, and health questionnaires. The study is divided into two parts: an early stage that looks primarily at remission rates, and a later stage that also compares how long patients survive.

Throughout the trial, doctors will watch for side effects and any changes in how the disease behaves. Patients will have routine check‑ups, lab work, and imaging as needed to ensure safety and to track the disease. After the treatment period, follow‑up visits continue for a period to monitor long‑term outcomes and quality of life.

This is an open‑label, phase 3 study, meaning that both doctors and participants know which medicines are being given and the research is at an advanced stage. After giving informed consent, participants are randomly assigned—by chance—to receive either the new combination or one of the standard combinations, and they take the pills daily. Throughout the study, participants have regular doctor visits and simple scans to check the size of the cancer, and they report any side effects, while the overall health and quality of life are also monitored over several months.

The purpose of the study is to evaluate the antitumor effect of the drug combinations in people with resectable, EGFR‑mutated stage II‑IIIB disease when given in a neoadjuvant setting, meaning the treatment is given before the tumor is removed.

Participants receive the assigned medication(s) for several weeks, then undergo surgery to remove the tumor, and continue to be monitored for safety and how well the cancer responded. The study follows each person from the start of treatment through surgery and the recovery period, collecting information about any side effects and the amount of cancer left after the operation.

The main aim is to evaluate how safe the treatment is, to determine the appropriate dose, and to see whether the treatment can be given as planned. Researchers will watch for dose‑limiting toxicities (DLT), which are side effects that prevent increasing the dose, and will identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D). All side effects will be graded using the standard CTCAE system, which classifies how severe each reaction is.

Participants will first have blood drawn so their T cells can be collected and modified. After a short waiting period, the modified cells are infused, and patients will be monitored regularly with clinic visits, blood tests, and imaging scans to check for side effects and any changes in tumor size. Tumor response will be assessed using the widely accepted RECIST criteria, which define an objective response rate as the proportion of patients whose tumors shrink by a predetermined amount.

The purpose of the trial is to evaluate whether the combination of these two medicines is safe and can improve how long the disease stays under control. Participants will first take the oral tablet alone for three treatment cycles, then the injection will be added while the tablet continues, for a total of about two years of therapy. Throughout the study, regular doctor visits, blood tests, and imaging scans will be performed to watch for side effects, check the amount of cancer in the blood and bone marrow, and assess overall health.

The purpose of the study is to see how well this combination works and how safe it is for people whose disease has come back after previous therapy. Participants will receive the medicines on a regular schedule, attend clinic visits for check‑ups, have blood drawn, and may have other simple tests to monitor how the disease is responding and to watch for any side effects.

The study continues for several months, during which doctors will look for any improvement in the cancer, record any problems that arise, and follow participants after treatment ends to see how long any benefit lasts.

The purpose of the study is to determine whether the experimental drug, alone or together with the blood‑vessel‑blocking drug, can improve overall survival compared with the standard pill combination plus the blood‑vessel‑blocking drug.

Participants are randomly placed into one of three groups: one group receives the experimental drug alone, a second group receives the experimental drug combined with the blood‑vessel‑blocking drug, and a third group receives the standard pill combination together with the blood‑vessel‑blocking drug. Treatments are given in repeated cycles, and participants have regular clinic visits for check‑ups, blood tests, imaging scans, and monitoring for side effects. The study continues until the disease progresses or the treatment can no longer be tolerated.

Participants will take one 70 mg capsule by mouth each day for a period that may last several months. Throughout the study they will attend regular clinic visits where doctors will perform physical exams, blood tests, and imaging scans such as CT scans to measure tumor size using standardized criteria known as RECIST. The study will also monitor any side effects, track changes in quality of life, and record how long any tumor response lasts.

Participants will be given the assigned medicines by IV infusion or by mouth in repeated cycles that last a few weeks, and they will have regular doctor visits, blood tests, and imaging scans to see how the tumors are responding. Doctors will use a standard system called RECIST to measure changes in tumor size, and side effects will be recorded using the grading system known as CTCAE. The study will track how long the cancer stays under control, described as progression‑free survival, and how long participants live, described as overall survival, along with any side effects that occur.

After the gadobutrol injection, blood samples will be taken at several time points to see how the substance moves through the body, and the children will continue their regular chemotherapy schedule. Participants will be observed for any immediate reactions for about half an hour after the injection and will be asked about common symptoms such as headache, nausea, or dizziness during the first week. Additional follow‑up visits will include simple questionnaires that measure mental fatigue and more detailed tests of thinking and memory at three months, and again at two years, to check for any changes in brain function. All procedures are designed to be as safe and comfortable as possible while gathering information that could help tailor future treatments.

The purpose of the study is to see whether adding Rinatabart Sesutecan can keep the cancer from growing for a longer time compared with the usual treatment alone. Participants are randomly placed into one of the two groups after completing their second‑line chemotherapy, then they receive the assigned maintenance therapy for several months while doctors monitor their health through regular clinic visits and scans.

Progression‑free survival means the period during which the cancer does not get worse. Doctors use a set of rules called RECIST to measure whether tumors have grown or shrunk on imaging tests. To understand how the treatments affect overall well‑being, participants also complete a questionnaire known as the EORTC QLQ‑C30, which asks about symptoms, daily activities, and overall quality of life.

Two treatments are being compared. The experimental drug, identified by the code name JNJ-79635322, is a laboratory‑created protein that can bind to three different targets on cancer cells, helping the immune system recognize and attack them. The standard comparator is teclistamab, another laboratory‑created protein that works in a similar way. Both medicines are given as a subcutaneous injection (placed under the skin). The experimental agent is a type of monoclonal antibody, a class of drugs that act like a guided missile for the immune system.

The purpose of the trial is to compare how well the two drugs work in controlling the disease. Participants are randomly assigned to receive either the experimental drug or the comparator, with regular treatment sessions over several months and periodic clinic visits for safety checks and blood testing. The study continues until a predefined period has passed or the disease progresses.

The purpose of the study is to find out whether the combination of the two hormones keeps the blood level of TSH (a test that shows how well the thyroid system is working) within the target range more often than levothyroxine by itself. Volunteers are randomly placed into one of the two medication groups at the same time they start the cancer drug. Over roughly six months they visit the clinic for regular blood checks, answer quality‑of‑life questionnaires, and are monitored for any side effects. The study looks at how often the hormone levels stay in the desired range and whether the treatment is safe.

The study is designed to understand how well these treatments work together and how safe they are for patients. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in different groups, with some participants receiving Raludotatug Deruxtecan with Carboplatin, others with Paclitaxel, and another group with Bevacizumab. The goal is to find the best combination that offers the most benefit with the least side effects.

Throughout the study, researchers will closely monitor participants for any side effects and how their cancer responds to the treatment. The study will help determine the most effective and safe way to use these medications for treating these specific types of cancer. The trial is expected to continue for several years to gather enough information to make informed conclusions about the treatments being tested.

The purpose of the trial is to determine how a high-fat meal influences the pharmacokinetics of the drug—meaning how quickly and how much of the medication enters the bloodstream—and to observe any changes in steroid hormone levels such as testosterone over time. Healthy male volunteers receive the tablet twice: once after an overnight fast and once after eating a fatty meal, with a short break between the two dosing periods.

During each visit, blood samples are collected at several time points to measure the amount of drug and hormone levels in the plasma, the liquid part of blood. Participants are monitored for any side effects throughout the short study period, and all procedures are designed to be safe and well‑tolerated.

One medicine used is tirzepatide, which belongs to a class called GLP-1/GIP receptor agonist. It is given as a subcutaneous injection, meaning the drug is injected just under the skin. Another medicine is letrozole, a pill taken by mouth that blocks estrogen, a hormone that can help some breast cancers grow. The goal is to see whether these drugs, alone or together, can slow tumor growth, which is described as an anti‑proliferative effect, meaning they may reduce the speed at which cancer cells multiply. Researchers will also watch for any adverse events, or side effects, and will check blood for small pieces of tumor genetic material known as circulating tumor DNA to learn more about the disease.

The purpose of the trial is to compare the change in a cell‑growth marker called KI67 between the start of treatment and the time of surgery across the different treatment groups. Participants will receive the assigned medication(s) for a short period before surgery, undergo the planned operation, and then have follow‑up visits to monitor recovery and any side effects.

The main goal of the trial is to see whether adding obrixtamig to the standard chemotherapy can improve overall survival, meaning the length of time patients live after starting treatment.

Participants will receive the regular platinum‑based chemotherapy according to usual schedules and will also receive an intravenous infusion of obrixtamig during the same treatment cycles. After the treatment period, patients will be monitored for several months to track their health status and any side effects, with regular visits to assess how well the cancer is controlled and to record survival outcomes.

All participants receive the standard drugs in R-mini-CHOP, which include the antibody rituximab and several chemotherapy agents. In the experimental group, patients also receive epcoritamab, which is given as a small injection under the skin (subcutaneous). The standard group receives only the usual chemotherapy and the antibody given either by vein (intravenous) or under the skin, depending on the usual practice.

Participants are randomly assigned to one of the two treatment plans and go through a series of treatment cycles over several months. After the treatment period, regular check‑ups are performed to see whether the cancer has disappeared completely (called complete remission) or whether it has returned. The study follows patients for a period of time after treatment to monitor their health and any side effects.

The main goal of the trial is to see whether the combination is safe and can be given before surgery, and to determine if it can increase the chance that no cancer cells are left in the tissue removed during the operation, known as a pathological complete response (meaning the tumor disappears under the microscope). Participants will receive several cycles of the infusion treatment over a few months, followed by surgery to remove the tumor, and then they will be monitored for any side effects and for how well the cancer responds. The study follows patients from the first dose through the surgery period and continues to track their health for a period after treatment.